Results 61 to 70 of about 31,911 (153)
ABSTRACT Background Acute myeloid leukemia (AML) is difficult to distinguish from lymphoblastic leukemia or lymphoma (LL) on morphologic features alone. Therapeutic approaches for AML versus LL differ, and immediate therapy is often needed due to patient illness and rapid disease progression.
Mayzie Miller +4 more
wiley +1 more source
ABSTRACT BCL6 is a master transcriptional regulator of germinal center (GC) B cells. BCL6 is frequently translocated at the major translocation cluster (MTC) within intron 1 of the BCL6 locus, a hotspot commonly rearranged in diffuse large B cell lymphomas (DLBCLs).
Santosh Kumar Gothwal +4 more
wiley +1 more source
Histiocytosis development and clinical variation through the lens of genomics
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps +3 more
wiley +1 more source
Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi +17 more
wiley +1 more source
Goniothalamin (GTN) exerts anticancer effects by promoting reactive oxygen species (ROS) generation, glutathione (GSH) depletion, DNA damage, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction. These interconnected events trigger apoptosis, necroptosis, anoikis, and autophagy, while modulating mitogen‐activated protein kinase (MAPK ...
Nataša Joković +6 more
wiley +1 more source
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Tisagenlecleucel is a CD19-specific chimeric antigen receptor (CAR)-T cell therapy approved for patients aged ≤25 years with relapsed or refractory B cell precursor acute lymphoblastic leukemia (B-ALL) and adults with relapsed or refractory diffuse large
Seshu Tyagarajan +2 more
doaj +1 more source
Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar +12 more
wiley +1 more source
Nucleotide Metabolism in Health and Disease
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao +7 more
wiley +1 more source
Childhood Lymphoblastic Lymphoma: Hospital Based Study.
Background: Lymphoblastic lymphomas (LBL) are neoplasms of precursor T cells and B cells, or lymphoblasts. The term lymphoblastic lymphoma has been used to describe predominantly lymph node– based disease; however, clinical distinction between LBL and ...
Samaher A. Fadhil +3 more
doaj +1 more source
Genetic analysis of primary lung interdigitating dendritic cell sarcomas
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov +6 more
wiley +1 more source

